Fms-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML). FLT3 internal tandem duplication (ITD) plays an important role in shaping the clinical ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Meanwhile, kinase inhibitors with FLT3 activity - including Pfizer's Sutent (sunitinib), Bayer/Onyx' Nexavar (sorafenib), and Ariad Pharma's Iclusig (ponatinib) - have shown some activity in AML ...

with the small-molecule protein kinase inhibitor midostaurin (Rydapt, Novartis) in combination with chemotherapy. Midostaurin, which targets the FLT3 receptor (WT and/or mutant), was approved by ...